...
首页> 外文期刊>Bulletin du Cancer: Journal de l'Association Francaise pour l'Etude du Cancer >Lymph node dissection: What for? From esophagus to rectum: Surgical and lymph node related prognostic factors [De l'?sophage au rectum: Les facteurs pronostiques ganglionnaires et chirurgicaux]
【24h】

Lymph node dissection: What for? From esophagus to rectum: Surgical and lymph node related prognostic factors [De l'?sophage au rectum: Les facteurs pronostiques ganglionnaires et chirurgicaux]

机译:淋巴结清扫术:干什么用?从食道到直肠:手术和淋巴结相关的预后因素[从食道到直肠:神经节和手术的预后因素]

获取原文
获取原文并翻译 | 示例
   

获取外文期刊封面封底 >>

       

摘要

Surgery has still a key role in curative treatment of digestive carcinomas, and for almost all localisations, lymph node status is a major prognostic factor. As far as oesophageal and gastric cancer are concerned, there is not yet any internationally standardized approach. Occidental guidelines recommend more limited lymph node dissections than Asiatic ones. Lymph node numbers requested during surgery of such cancers remain high, at least 23 lymph nodes for oesophageal cancer, and 25 for a D2 or D1.5 lymphadenectomy for gastric cancer. Generalisation of neo-adjuvant and adjuvant treatments has not yet modified these standards. On the other hand, rectal cancer surgery is well standardized since the global adoption of Total Mesorectal Excision (TME) for the late eighties. Development of mini-invasive techniques (laparoscopy and robot-assisted surgery) enabled an important decrease of surgery related morbidity as well as an enhanced post-operative recovery. However, rectal cancer surgery still has an important morbidity. Development of neo-adjuvant chemo-radiotherapy as well as in-depth knowledge of risk factor of lymph node invasion opened up the path for transanal full thickness resection without lymphadenectomy. The goal of such an approach is to avoid TME's morbidity without risking local recurrence rate increase. As a consequence, this technique might need to be completed with a TME case histological factors are not favorable.
机译:手术在消化道癌的根治性治疗中仍然发挥着关键作用,对于几乎所有部位,淋巴结状况都是主要的预后因素。就食道癌和胃癌而言,还没有任何国际标准化的方法。西方指南建议淋巴结清扫术比亚洲淋巴结清扫术更有限。在此类癌症的手术过程中,要求的淋巴结数目仍然很高,食管癌至少为23个淋巴结,而胃癌的D2或D1.5淋巴结清扫术则为25个。新辅助和辅助治疗的普遍化尚未修改这些标准。另一方面,自八十年代末全球全面采用直肠系膜切除术(TME)以来,直肠癌手术已得到了很好的标准化。微创技术(腹腔镜检查和机器人辅助手术)的发展使与手术相关的发病率大大降低,并提高了术后恢复率。但是,直肠癌手术仍具有重要的发病率。新辅助化学放疗的发展以及对淋巴结侵袭危险因素的深入了解,为不进行淋巴结清扫术的经肛门全厚度切除开辟了道路。这种方法的目标是避免TME的发病,而不会冒局部复发率增加的风险。结果,可能需要在TME情况下完成此技术,而组织学因素不利。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号